They don't have much control over price, apart from optimising production of high value products and offering differing pricing levels for on time delivery, a premium for quality and environmental sustainability, etc. They are ramping up volume with phase 2 now fully operational and focusing on sorting sx issues. Increased production leads to lower unit cost. As they are currently making payments under the the take or pay clause, costs will be further reduced if they are able to successfully renegotiate the supplier contract.
I believe that if they can sort out the issues mentioned and ramp up to steady state production of 16000tpa, they do not need very high selling prices. Average selling price of US$20m should be more than adequate in my view.
- Forums
- ASX - By Stock
- LYC
- Lynas Business Plan
Lynas Business Plan, page-21
Featured News
Add LYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$7.14 |
Change
-0.200(2.72%) |
Mkt cap ! $6.673B |
Open | High | Low | Value | Volume |
$7.34 | $7.34 | $7.13 | $39.28M | 5.467M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1546 | $7.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$7.15 | 72361 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 25876 | 7.120 |
2 | 280 | 7.110 |
4 | 14033 | 7.100 |
2 | 77850 | 7.090 |
2 | 13233 | 7.080 |
Price($) | Vol. | No. |
---|---|---|
7.150 | 72361 | 6 |
7.160 | 1420 | 1 |
7.170 | 10329 | 1 |
7.180 | 10329 | 1 |
7.190 | 10329 | 1 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
LYC (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online